Phase I/II study of RGX-121 in pediatric patients with Mucopolysaccharidosis Type II (MPS II)
Phase of Trial: Phase I/II
Latest Information Update: 04 Jan 2018
At a glance
- Drugs RGX 121 (Primary)
- Indications Mucopolysaccharidosis II
- Focus Adverse reactions; Therapeutic Use
- 04 Jan 2018 According to a Regenxbio media release, interim update from this trial is expected in late 2018.
- 22 Dec 2017 Planned number of patients changed to 6.
- 19 Dec 2017 According to a Regenxbio media release, the Investigational New Drug application (IND) is active for this planned trial, and the trial enrollment is expected to begin during the first half of 2018.